Skip to main content
Daan Gene Co., Ltd. logo

Daan Gene Co., Ltd. — Investor Relations & Filings

Ticker · 002030 ISIN · CNE000001KP1 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,189 across all filing types
Latest filing 2026-05-19 AGM Information
Country CN China
Listing Shenzhen Stock Exchange 002030

About Daan Gene Co., Ltd.

https://www.daangene.com

Daan Gene Co., Ltd. specializes in the development and manufacturing of molecular diagnostic products and services. The company focuses on in vitro diagnostic technologies, particularly polymerase chain reaction (PCR) platforms. Its product portfolio includes diagnostic kits for infectious diseases, genetic screening, and oncology, alongside automated nucleic acid extraction systems and real-time PCR instruments. Daan Gene provides comprehensive solutions for clinical laboratories and public health institutions, integrating research, production, and clinical testing services. The organization emphasizes technological innovation in molecular biology to support precision medicine and disease control.

Recent filings

Filing Released Lang Actions
2025年度股东会法律意见书
AGM Information Classification · 82% confidence The document is a legal opinion (“法律意见书”) issued by a law firm concerning the convening, attendance, procedural compliance, and vote results of the company’s 2025 Annual General Meeting. It is not itself the annual report or interim financial statements, nor a securities transaction or financing notice, nor a simple results table. It is part of the AGM materials—precisely the legal opinion provided as supporting documentation for the AGM—and thus best fits the “AGM Information” category (code AGM-R).
2026-05-19 Chinese
广州达安基因股份有限公司简式权益变动报告书
Major Shareholding Notification Classification · 95% confidence The document is a Simplified Equity Change Report (“简式权益变动报告书”) filed on Shenzhen Stock Exchange, detailing a transfer of substantial shareholdings among controlling shareholders and the resulting change in equity percentages. It is neither an annual/interim financial report nor a notice of dividend or delisting. It specifically discloses a change in significant share ownership levels (crossing thresholds) by major shareholders, fitting the definition of a Major Shareholding Notification. Hence, it should be classified as MRQ.
2026-05-15 Chinese
万联证券股份有限公司关于广州达安基因股份有限公司详式权益变动报告书之财务顾问核查意见
M&A Activity Classification · 91% confidence The document is the Financial Advisor’s Verification Opinions (“财务顾问核查意见”) attached to a “详式权益变动报告书” (Detailed Equity Change / Takeover Report) for a control change in a listed company. It is not merely an announcement or a proxy statement but the full regulatory takeover report prepared under Chinese M&A disclosure rules (Guidelines No.15 & 16, Securities Law, Takeover Rules). Therefore, it falls under M&A Activity (Code: TAR).
2026-05-15 Chinese
广州达安基因股份有限公司详式权益变动报告书
Major Shareholding Notification Classification · 92% confidence The document is a detailed “Equity Change Report” (详式权益变动报告书) filed by an information disclosure obligor regarding a large share transfer and change in shareholding percentages for a listed company, which is exactly the type of disclosure made when crossing significant shareholding thresholds. This aligns with the “Major Shareholding Notification” category (MRQ).
2026-05-15 Chinese
关于召开2025年度股东会的通知
Regulatory Filings
2026-04-27 Chinese
关于会计师事务所2025年度履职情况的评估报告
Regulatory Filings
2026-04-27 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.